CEFTRIAXONE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CEFTRIAXONE IN PLASTIC CONTAINER (CEFTRIAXONE IN PLASTIC CONTAINER).
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged in the urine (33-67%) and bile (up to 40%). It undergoes minimal hepatic metabolism. |
| Excretion | Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites). |
| Half-life | 5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment. |
| Protein binding | 85-95% bound to albumin. |
| Volume of Distribution | 0.2-0.4 L/kg; indicates extensive distribution into interstitial fluid and tissues. |
| Bioavailability | IM: 100%. |
| Onset of Action | IV: Immediate; IM: 1-2 hours. |
| Duration of Action | 24 hours; allows once-daily dosing due to prolonged half-life. |
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 10-50 mL/min: no adjustment needed; for GFR <10 mL/min: maximum dose 2 g every 24 hours. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B and C: no dosage adjustment required as hepatic metabolism is minimal. |
| Pediatric use | 50-75 mg/kg/day intravenously or intramuscularly divided every 12-24 hours, maximum 2 g/day. |
| Geriatric use | No specific adjustment except based on renal function; monitor renal function and adjust per creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CEFTRIAXONE IN PLASTIC CONTAINER (CEFTRIAXONE IN PLASTIC CONTAINER).
| Breastfeeding | Ceftriaxone is excreted into human breast milk in low concentrations (M/P ratio approximately 0.04). It is considered compatible with breastfeeding by the American Academy of Pediatrics. However, caution should be exercised due to potential for alteration of infant gut flora and allergic sensitization. |
| Teratogenic Risk | Ceftriaxone is a pregnancy category B drug. Animal studies have not demonstrated fetal risk, and there are no adequate well-controlled studies in pregnant women. However, it should be used during pregnancy only if clearly needed. No known teratogenic effects in first trimester; potential for bilirubin displacement in third trimester, but clinical significance is minimal. |
■ FDA Black Box Warning
None. Ceftriaxone does not have an FDA black box warning.
| Serious Effects |
["Hypersensitivity to ceftriaxone or any cephalosporin","Hypersensitivity to penicillins (cross-sensitivity; caution)","Neonates with hyperbilirubinemia (ceftriaxone displaces bilirubin from albumin)","Neonates requiring calcium-containing IV fluids (risk of ceftriaxone-calcium precipitation)","Do not use in combination with calcium-containing solutions in neonates ≤28 days"]
| Precautions | ["Hypersensitivity reactions, including anaphylaxis, have been reported.","Clostridium difficile-associated diarrhea (CDAD) may occur.","Concomitant use with calcium-containing IV solutions can cause fatal precipitation in neonates.","Hemolytic anemia, immune-mediated, has been reported.","Seizures may occur in patients with renal impairment receiving high doses.","Biliary pseudolithiasis has been observed.","Prolonged prothrombin time possible; monitor in patients with vitamin K deficiency."] |
| Food/Dietary | No specific food interactions, but avoid alcohol due to disulfiram-like reaction (nausea, vomiting, headache). |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond routine pregnancy care. Observe for signs of maternal allergic reactions, diarrhea (Clostridium difficile colitis), and neonatal effects if administered near delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data insufficient to determine impact. |
| Clinical Pearls | Administer IV over 30 minutes; do not mix with calcium-containing solutions (risk of precipitation). Use with caution in neonates with hyperbilirubinemia (displaces bilirubin). Monitor renal function during therapy. Can cause biliary sludge/pseudolithiasis. Antagonized by chloramphenicol. |
| Patient Advice | This medication is given intravenously; tell your nurse if you experience pain or redness at the injection site. · Report any signs of allergic reaction: rash, itching, swelling, difficulty breathing. · Diarrhea is common; contact your doctor if severe or bloody diarrhea occurs (may indicate C. diff). · Do not drink alcohol during treatment and for 48 hours after stopping (risk of disulfiram-like reaction). · Inform your doctor if you have a history of gallbladder problems (ceftriaxone can cause gallbladder sludge). |